ArticleBMC bioinformatics2025
Literature data-based de novo candidates for drug repurposing.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDrug repurposing offers a promising strategy for drug discovery. Drug repurposing involves identifying new therapeutic indications for existing, marketed drugs, thereby reducing the risks, costs, and time typically required for drug development. Various methods exist for drug repurposing, including high-throughput screening of drug compound libraries, computation in silico approaches, literature-based methods, etc. Currently, numerous methods utilize literature for data mining in drug repositioning; however, relatively few approaches leverage literature citation networks for this purpose.
resultsWe identified 19,553 potential drug pairs for repurposing by analyzing biomedical literature data through the Jaccard coefficient. Our results demonstrated that the literature-based Jaccard coefficient was the most effective similarity metric for identifying drug repurposing opportunities. To refine our selection process, we applied a threshold defined by the upper γth quantile value of the Jaccard coefficient, enabling us to prioritize promising de novo drug repurposing candidates. Among the identified drug pairs, we found several with strong potential for repurposing, including combinations such as adapalene and bexarotene, guanabenz and tizanidine, alvimopan and methylnaltrexone, etc.
conclusionWe created a validation set consisting of both true positives and true negatives for drug pairs using the repoDB dataset, a widely recognized resource for drug repurposing. To evaluate the performance of various similarity metrics for drug pairs, we compared their effectiveness based on AUC, F1 score, and AUCPR using the validation set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.